Ke Geng

Partner

Disclaimer

Thank you for your interest. Before you communicate with one of our attorneys, please note: Any comments our attorneys share with you are general information and not legal advice. No attorney-client relationship will exist between you or your business and O’Melveny or any of its attorneys unless conflicts have been cleared, our management has given its approval, and an engagement letter has been signed. Meanwhile, you agree: we have no duty to advise you or provide you with legal assistance; you will not divulge any confidences or send any confidential or sensitive information to our attorneys (we are not in a position to keep it confidential and might be required to convey it to our clients); and, you may not use this contact to attempt to disqualify O’Melveny from representing other clients adverse to you or your business. By clicking "accept" you acknowledge receipt and agree to all of the terms of this paragraph and our Disclaimer.

Ke Geng, managing partner of the Beijing office, advises Chinese companies in connection with outbound investments and exchange listings in the United States or Hong Kong, as well as the privatization of US or HK listed companies, private equity and venture capital financing, mergers and acquisitions transactions, and general corporate matters. Ke provides client-oriented, proactive, and cost-effective services to companies spanning a wide variety of industries, including healthcare, technology, media, and telecommunications (TMT).

Prior to joining O’Melveny, Ke practiced at another large international law firm.

Professional Activities

Publications

“Should China Provide Intellectual Property Protection for Genetically Modified Animals?” Northwestern Journal of International Law and Business (Winter 2003)

Offshore Public Offerings

Represented Bank of Qingdao (03866.HK) in its US$531 million IPO and listing on the Hong Kong Stock Exchange

Represented Shanghai Haohai Biological (6826.HK) in its US$300 million IPO and listing on the Hong Kong Stock Exchange

Represented Credit Suisse and China Renaissance as joint bookrunners in the US$53 million initial public offering and NYSE listing of ADS of Jupai Holdings Limited (NYSE: JP)

Represented eHi Car Services (NYSE: EHIC) in its US$120 million IPO and listing on the NYSE

Represented Phoenix Healthcare (01515.HK) in its US$220 million IPO and listing on the Hong Kong Stock Exchange

Represented Credit Suisse and an American multinational banking and financial services holding company as joint bookrunners in the US$110 million IPO and listing on the NYSE of Leju Holdings Ltd. (NYSE: LEJU)

Represented Credit Suisse and Goldman Sachs as joint bookrunners in US$138 million IPO of Tarena Technologies Inc. (NASDAQ:TEDU) on the NASDAQ

Represented Morgan Stanley, Credit Suisse and Citigroup as lead underwriters on the US$215 million US IPO of 58.com (NYSE: WUBA)

Represented Hengxing Gold (2303:HK) in its HK$330.4 million (approximately US$47 million) IPO and listing on the Hong Kong Stock Exchange

Represented Montage (NASDAQ: MONT) in its US$70 million IPO and listing on NASDAQ

Represented Pudong Science and Technology Investment (PDSTI) in its US$100 million investment in Icon Aircraft, Inc.

Represented Jiangsu Phoenix Education Publishing Co., Ltd. in its US$80 million acquisition of the assets relating to the children’s book business of Publication International Ltd. (PIL) and PIL’s subsidiaries

Represented PDSTI in its acquisition of 14.9% of outstanding shares of common stock of LightPath (NASDAQ: LPTH), a US optical instrument manufacturer